HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Harty, L. Articles by Power, A. Search for Related Content PubMed PubMed Citation Articles by Harty, L. Articles by Power, A.

Race and Ethnicity in the Era of Emerging Pharmacogenomics

From Clinical Research and Development, Pfizer Global Research and Development, New London, Connecticut (Dr Harty and Dr Power) and Clinical Research and Development, Pfizer Global Research and Development, Ann Arbor, Michigan (Dr Johnson).

Race and ethnicity are terms that are commonly used to categorize subjects in medical research. Advances in genetics and the emerging discipline of pharmacogenomics have brought these terms under scrutiny, with arguments either for the continued use or for the abandonment of these terms generating strong views. As pharmacogenomics research develops, we may find that more accurate and specific descriptions of relevant variation in genes will reduce the value that these imprecise descriptors have in predicting how people will respond to drug therapies.

Key Words: Pharmacogenomics • race • ethnicity • genetics

Address for reprints: Aidan Power, MB, BCh, MRCPsych, Pfizer Global Research and Development, 50 Pequot Avenue, New London, CT 06320; e-mail: aidan.c.power{at}pfizer.com.

This article has been cited by other articles:

				R. Temple and N. L. Stockbridge BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective Ann Intern Med, January 2, 2007; 146(1): 57 - 62. [Abstract] [Full Text] [PDF]